<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489173</url>
  </required_header>
  <id_info>
    <org_study_id>BOOG 2019-01</org_study_id>
    <nct_id>NCT04489173</nct_id>
  </id_info>
  <brief_title>TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer</brief_title>
  <acronym>TIBET</acronym>
  <official_title>A Phase 2 Study of Trifluridine/Tipiracil in Patients With ER-positive, HER2-negative Advanced Breast Cancer That Previously Received Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BOOG Study Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Borstkanker Onderzoek Groep</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter phase 2 study evaluating the efficacy and safety of&#xD;
      trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not&#xD;
      amenable to curative treatment by surgery or radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in&#xD;
      women with metastatic or locally advanced breast cancer not amenable to curative treatment by&#xD;
      surgery or radiotherapy. This study will be conducted under the sponsorship of BOOG,&#xD;
      Amsterdam, NL.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To evaluate the efficacy of trifluridine/tipiracil by determination of the percentage of&#xD;
      patients being progression free at 8 weeks on trifluridine/tipiracil prescribed for&#xD;
      ER-positive, HER2-negative advanced breast cancer patients previously treated with a taxane&#xD;
      and capecitabine.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Progression-free survival Response rate CR/PR at 16 weeks Adverse events Translational&#xD;
      research on biological factors that may be of influence on the outcome of treatment QoL&#xD;
&#xD;
      Main eligibility criteria:&#xD;
&#xD;
      Metastatic Her2 negative, ER-positive breast cancer patients that progressed on, or after&#xD;
      treatment with Capecitabine. Previous treatment with Taxanes is obligatory. Adequate&#xD;
      hematology, liver and renal function tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, single arm, phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.&#xD;
Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.&#xD;
Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>16 weeks</time_frame>
    <description>Response rate CR/PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>32 weeks</time_frame>
    <description>Quality of Life questionnaire EORTC QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Neoplasm</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with TAS102</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trifluridine/tipiracil</intervention_name>
    <description>Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.&#xD;
Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Lonsurf, TAS102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult women(≥ 18 years of age) with proven diagnosis of metastatic or locally advanced&#xD;
             breast cancer not amenable to curative treatment by surgery or radiotherapy&#xD;
&#xD;
          2. Documented ER positive (10%) and/or PR positive (10%) and HER2 negative metastatic&#xD;
             breast cancer&#xD;
&#xD;
          3. Progressive disease based on imaging&#xD;
&#xD;
          4. Women previously treated with capecitabine (in metastatic setting), and a maximum of&#xD;
             two other lines of chemotherapy including a taxane either in the (neo)adjuvant or&#xD;
             metastatic setting.&#xD;
&#xD;
          5. Evaluable disease as defined per RECIST v.1.1 (see Appendix B). Tumor lesions&#xD;
             previously irradiated or subjected to other locoregional therapy will only be deemed&#xD;
             measurable if disease progression at the treated site after completion of therapy is&#xD;
             clearly documented.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          7. Life expectancy of ≥ 12 weeks&#xD;
&#xD;
          8. Willing and able to comply with scheduled visits and study procedures&#xD;
&#xD;
          9. Adequate organ, bone marrow and coagulation function as shown by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 ×109/L&#xD;
&#xD;
               -  Platelets ≥ 75 ×109/L&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 5.6 mmol/L&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5&#xD;
                  ULN (or ≤ 5 if hepatic metastases are present)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for patients known to have Gilbert&#xD;
                  Syndrome)&#xD;
&#xD;
               -  Creatinine clearance ≥60 ml/min&#xD;
&#xD;
         10. Written informed consent obtained before any screening procedure and according to&#xD;
             local guidelines.&#xD;
&#xD;
         11. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical&#xD;
             procedures to NCI CTCAE version 4.0 Grade ≤1, except alopecia or other toxicities not&#xD;
             considered a safety risk for the patient at investigator's discretion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ&#xD;
             hybridization positive) and ER-negative patients are not eligible&#xD;
&#xD;
          2. No more than two lines of chemotherapy for advanced disease&#xD;
&#xD;
          3. Resolution of side-effects from previous chemotherapy &gt; grade 1 (except for alopecia)&#xD;
&#xD;
          4. Radiotherapy within four weeks prior to enrollment is not allowed except in case of&#xD;
             localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture&#xD;
             which can then be completed within two weeks prior to enrollment. Patients must have&#xD;
             recovered from radiotherapy toxicities prior to enrollment.&#xD;
&#xD;
          5. 30% or more marrow-bearing bone being irradiated. Other primary tumors within the last&#xD;
             5 years before study entry are not allowed, except for adequately controlled basal&#xD;
             cell carcinoma of the skin, or carcinoma in situ of the cervix.&#xD;
&#xD;
          6. Previous or current CNS metastases, carcinomatous meningitis, are not allowed. A CT or&#xD;
             MRI of the brain must be performed within 4 weeks prior to registration if the&#xD;
             presence of metastases at this site is suspected.&#xD;
&#xD;
          7. Evidence of clinically significant cardiovascular or pulmonary disease or any other&#xD;
             disease, metabolic or psychological dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug, or that may affect patient&#xD;
             compliance with study routines, or places the patient at high risk from treatment&#xD;
             related complications. (e.g lactose intolerance)&#xD;
&#xD;
          8. Previously received trifluridine/tipiracil&#xD;
&#xD;
          9. Since trifluridine/tipiracil contains lactose, patients with rare hereditary problems&#xD;
             of galactose intolerance, the Lapp lactase deficiency or glucose-galactose&#xD;
             malabsorption should not take this medicine&#xD;
&#xD;
         10. Diagnosis of any other malignancy prior to registration, except those that are not&#xD;
             believed to influence the patient's prognosis and do not require any further&#xD;
             treatment.&#xD;
&#xD;
         11. Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the investigator, would make the patient&#xD;
             inappropriate for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Elise van Leeuwen-Stok, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BOOG Study Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M.M.E.M. Bos, MD PhD</last_name>
    <phone>+31-107034897</phone>
    <email>m.bos@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>R.M. Bijlsma, MD PhD</last_name>
    <phone>+31 88 75 555 55</phone>
    <email>R.M.Bijlsma@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Beelen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelmina ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Heijns</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Groep</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M van Bekkum, MD</last_name>
    </contact>
    <investigator>
      <last_name>M van Bekkum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Imholz, MD</last_name>
    </contact>
    <investigator>
      <last_name>A Imholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B.E.P.J. Vriens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MC Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. De Graaf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M de Boer, MD</last_name>
    </contact>
    <investigator>
      <last_name>M de Boer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Bos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.M.L. Bijlsma</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAS102</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

